[ad_1]
PIC Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first-in-mechanism, first-in-class allosteric therapies targeting eIF4E, today announced it will present pre-clinical data on the company’s eIF4E program for ER+ breast cancer in a poster at the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13, 2022 in New Orleans, LA.
“The preclinical results highlighted in this poster underscore the unique therapeutic advantages of allosterically modulating eIF4E and further demonstrate its potential as a promising strategy for patients with ER+ breast cancer,” said Kathy Bowdish, Ph.D., president and chief executive officer of PIC Therapeutics.
PIC Therapeutics is targeting a fundamental mechanism at the convergence of many oncogenic signaling pathways, and results in cancer cell death while sparing normal cells. Allosteric modulation of eIF4E offers many advantages to previous approaches, and simultaneously addresses multiple drivers of pharmacology, allowing our small molecules to truly drive differential CAP dependent translation in target cells.
Importantly, preclinical studies show that PIC compounds modulate, but do not block protein translation. Consistently, our data demonstrate that as many proteins are upregulated as are downregulated as we alter protein complex membership. In ER+ breast cancer lines, PIC …
Full story available on Benzinga.com
[ad_2]
Source link
